𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-α antagonist infliximab

✍ Scribed by Dominique Reumaux; Nathalie Bardin; Jean-Frédéric Colombel; Françoise Dignat-George; Patrick Duthilleul; Séverine Vermeire

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
106 KB
Volume
13
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis

The authors thank D. Dehay (CH Valenciennes) for expert technical assistance, BioCytex Co. for providing reagents, V. Deken (Centre d'Etude et de Recherche en Informatique Me ´dicale, CHRU Lille), and INSERM U795 for their contribution to statistical analysis.

📜 SIMILAR VOLUMES

Serum lipopolysaccharide-binding protein
Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease
✍ Peter Laszlo Lakatos; Lajos Sandor Kiss; Karoly Palatka; Istvan Altorjay; Peter 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB 👁 1 views

## Background: In inflammatory bowel disease (ibd), enhanced inflammatory activity in the gut is thought to increase the risk of bacterial translocation and endotoxemia. in the present study we investigated the association between serum level of lipopolysaccharide-binding protein (lbp), soluble cd1

Sustained improvement of health-related
Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years
✍ Francesc Casellas; Luis Rodrigo; Pilar Niño; Carmen Pantiga; Sabino Riestra; Jua 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Background: Infliximab induces remission and improves the health-related quality of life (hrqol) of patients with refractory or fistulous crohn's disease (cd). however, little information is available as to whether its effect on hrqol is sustained over time. the objective was to measure the hrqo

Individualized monitoring of drug bioava
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b

Formation of antinuclear and double-stra
Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease
✍ Florian Beigel; Fabian Schnitzler; Rüdiger Paul Laubender; Simone Pfennig; Maria 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

Background: Anti-tumor necrosis factor (TNF) therapy used in patients with inflammatory bowel disease (IBD) has been associated with induction of autoantibodies including antinuclear antibodies (ANA), double-strand (ds) DNA antibodies, and the occurrence of lupus-like syndrome (LLS). However, the cl